Zynerba Pharma - About the company
Zynerba Pharma is an acquired company based in Devon (United States), founded in 2007. It operates as a Transdermal synthetic cannabinoid therapy to treat neurological disorders. Zynerba Pharma has raised $13M in funding from Perceptive Advisors. The company has 2895 active competitors, including 977 funded and 715 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.
Company Details
Zynerba Pharmaceuticals (formerly known as AllTranz) is focused on developing synthetic cannabinoid therapeutics for transdermal delivery. Using its proprietary transdermal technologies, it has developed a controlled delivery of therapeutic levels of two cannabinoids cannabidiol (CBD) and Tetrahydrocannabinol (THC). Its lead candidate ZYN002, a CBD gel, is being studied in refractory epilepsy, FXS, and osteoarthritis. It is also developing ZYN001 which uses pro-drug of THC in a transdermal patch to deliver THC and is currently being studied in fibromyalgia and peripheral neuropathic pain.
- Website
- www.zynerba.com
- Social
- Registered Address
- 80 W. Lancaster Avenue, Suite 300 Devon, PA 19333
Key Metrics
Founded Year
2007
Location
Devon, United States
Stage
Acquired
Total Funding
$13M in 8 rounds
Latest Funding Round
Investors
Ranked
1001st among 2895 active competitors
Annual Revenue
$0 - $1M as on Dec 31, 2018
Employee Count
9 as on Jun 30, 2026
Similar Companies
Exit Details
Acquired by Harmony Biosciences (Aug 14, 2023)
Legal entities associated with Zynerba Pharma
Zynerba Pharma is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Zynerba Pharmaceuticals, Inc. CIN: 1621443 , United States, Active | $0 - $1M (As on Dec 31, 2018) | - | - | |
Zynerba Pharmaceuticals, Inc. CIN: 26-0389433 , United States, Active | Jan 30, 2007 | - | 27 (As on Mar 31, 2023) | - |
Zynerba Pharma's acquisition details
Zynerba Pharma got acquired by Harmony Biosciences on Aug 14, 2023.
Click here to take a look at Zynerba Pharma's acquisition in detail
Sign up to download Zynerba Pharma's company profile
Zynerba Pharma's funding and investors
Zynerba Pharma has raised a total funding of $13M over 8 rounds. Its first funding round was on 2007. Its latest funding round was a Post IPO round on Jul 21, 2022 for $*****. 1 investor participated in its latest round. Zynerba Pharma has 9 institutional investors.
Here is the list of recent funding rounds of Zynerba Pharma:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 21, 2022 | 8734237 | Post IPO | 1792542 | 6884728 | 6145155 | 5677236 |
Oct 09, 2014 | 6055022 | Series B | 4365139 | 7046069 | 3544938 | 1999334 |
Jul 26, 2012 | 4676026 | Grant (prize money) | 4140247 | 2797878 | 2935764 |
Access funding benchmarks and valuations. Sign up today!View details of Zynerba Pharma's funding rounds and investors
Zynerba Pharma's founders and board of directors
Founder? Claim ProfileZynerba Pharma's employee count trend
Zynerba Pharma has 9 employees as of Jun 26. Here is Zynerba Pharma's employee count trend over the years:
Uncover Zynerba Pharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Zynerba Pharma's Competitors and alternates
Top competitors of Zynerba Pharma include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Zynerba Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
3rd | PTC Therapeutics 1998, South Plainfield (United States), Public | Developer of small molecule drugs for the treatment of rare diseases | $248M | 77/100 | |
4th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
5th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | _1545299782322.png?devicePixelRatio=2&height=30&width=30){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
1001st | Zynerba Pharma 2007, Devon (United States), Acquired | Transdermal synthetic cannabinoid therapy to treat neurological disorders | $13M | 42/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Zynerba Pharma's competitors? Click here to see the top ones
Zynerba Pharma's Investments and acquisitions
Zynerba Pharma has made no investments or acquisitions yet.
Reports related to Zynerba Pharma
Here is the latest report on Zynerba Pharma's sector:
News related to Zynerba Pharma
Filter this list•
Cannabinoid Clinical Trial Pipeline Gains Momentum With 50+ Companies Leading New TreatmentsGlobeNewswire•Aug 12, 2025•Zynerba Pharma
•
Harmony Biosciences completes acquisition of ZynerbaTipRanks•Sep 14, 2024•Harmony Biosciences, Zynerba Pharma
•
The M&A Class Action Firm Continues Investigating the Merger – CPRI, ZYNE, APGN, DBTXGlobeNewswire•Aug 15, 2023•Monteverde, Capri Holdings, Zynerba Pharma, Apexigen and 1 other
•
Harmony Biosciences to acquire Zynerba for up to $200M in cashSeeking Alpha•Aug 14, 2023•Zynerba Pharma, Harmony Biosciences
•
Halper Sadeh LLC Is Investigating Whether the Sale of Zynerba Pharmaceuticals, Inc. Is Fair to ShareholdersACROFAN•Aug 14, 2023•Halper Sadeh, Zynerba Pharma, Harmony Biosciences
•
Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational HighlightsGlobeNewswire•May 15, 2023•Zynerba Pharma
•
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsGlobeNewswire•Mar 28, 2023•Zynerba Pharma
•
Zynerba Pharma says not holding cash deposits or securities at Silicon Valley BankSeeking Alpha•Mar 14, 2023•Zynerba Pharma, SVB
•
Zynerba Pharma rises 6% on positive data from Fragile X syndrome treatment trialSeeking Alpha•Jan 11, 2023•Zynerba Pharma
•
Zynerba delaying release of late-stage top-line results for Fragile X syndrome candidateSeeking Alpha•Dec 21, 2022•Zynerba Pharma
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Zynerba Pharma
Explore our recently published companies
- Doug Ashy Building Materials - United States based, 1960 founded, Unfunded company
- Wingmate - New York based, Unfunded company
- Freehouse - Spain based, Unfunded company
- My Edu Advisor - Austin based, Unfunded company
- Freedom Aged Care - Brisbane based, Unfunded company
- Window Works - Knoxville based, 2005 founded, Unfunded company
